ArticleCardiovascular and interventional radiology2026
Irreversible Electroporation for Colorectal Liver Metastases: Long-term Outcomes from a Transatlantic Multicenter Study.
Article in Cardiovascular and interventional radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate safety and long-term oncologic outcomes of irreversible electroporation (IRE) for colorectal liver metastases (CRLM) across three high-volume expert centres. MATERIALS AND
methodsThis retrospective multicentre study included patients treated with IRE for unresectable and unablatable CRLM between 2012 and 2025. The primary outcome measure was local tumour progression free-survival (LTPFS). Secondary outcome measures included local control (LC) allowing repeat treatment, overall survival (OS), distant progression-free survival (DPFS), adverse events (AE; CTCAE v5.0) and length-of-hospital-stay.
resultsOverall, 162 patients underwent 191 IRE procedures for 219 tumours. Median follow-up was 33.7 months. Per-tumour LTPFS at 1, 2, and 3-years was 68.2%, 55.5%, and 52.6%. Tumours ≤ 3cm demonstrated superior LTPFS compared with tumours >3cm, with 1, 2 and 3-year LTPFS rates of 77.5%, 63.8%, and 60.3% versus 37.4%, 28.5, and 28.5%, (HR 2.89; 95% CI 1.82-4.60; p<0.001). LTPFS did not differ between centres (p = 0.80). Per-tumour LC rates at 1, 2, and 3-years were 97.4%, 95.7%, and 94.8%. OS at 1, 3, 5 and 10-years was 89.3%, 44.6%, 24.2%, and 14.0%. AEs occurred in 23.0% of procedures, predominantly grade 1-2 (72.7%); no grade 5 events occurred. Median hospital-stay was 1 day (IQR 1-2).
conclusionIRE is a feasible and safe treatment option in expert centres for selected patients with CRLM, ineligible for thermal ablation or resection. Tumour size is a key determinant of LTP, with superior outcomes in lesions ≤ 3cm. Local recurrences are frequently amenable to repeat local treatment, eventually resulting in durable LC in the majority of patients.
Indexed as
Identifiers
42778637What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.